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doi:10.1016/j.jmii.2012.05.002Kawasaki disease (KD) is a systemic vasculitis primarily affecting children who are younger than
5 years. The most serious complications are coronary artery aneurysms and sequelae of vascu-
litis with the subsequent development of coronary artery aneurysm. According to the litera-
ture, intravenous immunoglobulin (IVIG) plus high-dose aspirin (acetylsalicylic acid) were
standard treatment for KD, whereas low-dose aspirin (3-5 mg/kg/day) was used for thrombo-
cytosis in KD via antiplatelet effect. However, aspirin has been reported to have hemolytic
potential in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. We report
a child with G6PD-deficiency who has KD, and review the literature.
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Kawasaki disease (KD) is an acute febrile vasculitis of
unknown etiology first described by Tomisaki Kawasaki.1 KD
occurs worldwide and primarily affects young children
(younger than 5 years). The clinical characteristics of KD are
prolonged fever, conjunctivitis, diffuse mucosal inflamma-
tion, polymorphous skin rashes, indurative edema of theished by Elsevier Taiwan LLC. All rights reserved.
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skin of the fingertips, and nonsuppurative cervical lymph-
adenopathy.2,3 In some countries where newborn babies
receive Bacillus Calmette-Gue´rin (BCG) vaccination, KD has
been associated with erythematous induration or even
ulcerationof theBCGscars in one-third of affectedpatients.4
The most serious complications are coronary artery
aneurysms and sequelae of vasculitis, with coronary artery
aneurysms developing in 20-25% of untreated children.2,3,5
In developed countries, KD is currently the leading cause
of acquired heart diseases in children.2,6e8 A United States
multicenter study group established that a single high dose
of 2 g/kg intravenous immunoglobulin (IVIG) plus aspirin
could lower the incidence of aneurysms to 3-5%.9 The
treatment profile also had the effect of shortening the
duration of fever.8,9 Because coronary artery lesions (CAL)
occur at a mean of 9.5 days after the onset of illness, it is
important to diminish the severity of inflammation and
vasculitis as soon as possible to prevent progression to
CAL.10 However, because some children were intolerant to
high-dose aspirin, low-dose aspirin for antiplatelet effect
after acute stage KD was prescribed in these patients as
previously reported by Hsieh et al.11
Since the discovery that primaquine-induced hemolytic
anemia is attributable to glucose-6-phosphate dehydroge-
nase (G6PD) deficiency, many other drugs, including
aspirin, have been reported to have hemolytic potential in
individuals with this enzyme abnormality.12 There are
currently no English-language articles discussing KD with
associated G6PD deficiency. We report a case of a G6PD-
deficient child with KD, and review the literature focusing
on KD, aspirin, and G6PD deficiency.Case report
A 10-month-old boy (weight: 11.3 kg (90th to 97th
percentile for age; height: 80 cm) had been well until
admission, when fever, lethargy, irritability, rhinorrhea,
and intermittent vomiting developed, and oral intake
decreased after 3 days of fever. The patient was born full-
term and was delivered vaginally; the Apgar scores were 9
and 10 at 1 and 5 minutes, respectively. The results of
routine newborn metabolic screening tests performed in
Taiwan revealed G6PD deficiency, and the G6PD quantity
was 0.44 U/g hemoglobin (class II G6PD deficiency in World
Health Organization classification). He had been well
otherwise, reaching normal growth and development
milestones. His childhood immunization schedule report-
edly was up to date, and he had no known allergies to drugs
or foods. He did not attend a day care center and did not
have a known history of travel or toxin exposure.
The vital signs on Day 4 of feverwere: temperature 38.2C,
blood pressure 90/48mmHg, heart rate 142 beats/minute and
respiratory rate 27 breaths/minute. His conjunctivae were
injected and nonicteric, his throat was injected (swelling and
redness over throat), and he had two engorged lymph nodes in
the anterior triangle of the left side of his neck on Day 4 of
fever onset. The initial blood investigationswere:white blood
cell count, 13,100 cells/mL; segment/lymphocyte, 55/33%;
hemoglobin, 9.6 g/dL; platelet count, 339,000 cells/L; carbon
dioxide, 16.2mEq/L; aspartate transaminase, 25U/L; alanineaminotransferase, 13 U/L; albumin, 3.6 g/dL; and C-reactive
protein, 133.2 mg/L. Urinalysis was normal without pyuria.
Strawberry tongue with reddish lips, polymorphous skin
rashes over the trunk and limbs, and erythematous palms
were found on Day 5 after fever onset, symptoms compatible
with the diagnosis of KD. Due to the possible risk of acute
hemolytic anemia, high-dose aspirin was not prescribed for
this G6PD-deficient patient. The fever declined within
12hours after initial IVIGadministration (2 gm/kg in 12hours).
A cardiac echogram (on Day 4 before IVIG) revealed mild
dilatation of the left coronary artery (2.65 mm). He was dis-
charged on Day 8 and dipyridamole (3 mg/kg/day) instead of
low-dose aspirin was prescribed to prevent thrombocytosis.
We prescribed neither high-dose nor low-dose aspirin for this
patient during his treatment course; however, he experi-
enced good recovery fromCAL (2.17mm) at 6-week follow-up
examination.
Discussion
Aspirin has been used in the treatment of KD for many
years, even earlier than the use of IVIG in KD. Although
aspirin has important anti-inflammatory (at high dose) and
antiplatelet (at low dose) activity, it does not appear to
lower the frequency of the development of coronary
abnormalities.6,11 During the acute phase of illness, aspirin
is administered at 80 to 100 mg/kg per day in four doses.
High-dose aspirin and IVIG appear to possess an additive
anti-inflammatory effect. Practices regarding the duration
of high-dose aspirin administration vary across institutions
(from 30-50 to 80-100 mg/kg/day),11 and many centers
reduce the aspirin dose after the child has been afebrile for
48 to 72 hours. Other clinicians continue high-dose aspirin
until Day 14 of illness and 48 to 72 hours after fever
cessation.8,11 When high-dose aspirin is discontinued,
a low-dose aspirin regimen (3-5 mg/kg/day) is begun and
maintained until the patient shows no evidence of coronary
changes by 6 to 8 weeks after the onset of illness.8 For
children who develop coronary abnormalities, aspirin may
be continued indefinitely.8,13 However, Reye syndrome is
a risk in children who take salicylates while they are
experiencing active infection with varicella or influenza,
and has been reported in patients taking high-dose aspirin
for a prolonged period after KD.14 Hsieh et al11 reported
that nonaspirin treatment of acute KD had no effect on the
response rate of IVIG therapy, duration of fever, or inci-
dence of CAL when children were treated with high-dose
IVIG as a single infusion. It seems unnecessary to expose
children with acute KD to high-dose aspirin, especially
those with G6PD deficiency. However, in the literature,
low-dose aspirin has been prescribed for at least 6-8 weeks
to prevent thrombocytosis in patients with KD because of
the antiplatelet effect.8 If patients had an allergic reaction
or intolerance to a particular drug, clinicians must dis-
continue its use and look for alternatives. Aspirin was used,
often in conjunction with dipyridamole, in most patients.
Dipyridamole has been used to treat patients with a coro-
nary aneurysm resulting from KD.15,16
The relationship between aspirin therapy and hemolytic
disorder in G6PD- deficient patients is unclear. Also, there
is no literature discussing the use of low-dose aspirin and
outcome of KD. G6PD deficiency, an X-linked disorder, is
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humans. The clinical expression of G6PD deficiency
encompasses a spectrum of hemolytic syndromes. Although
affected patients are usually asymptomatic, some have
episodic anemia whereas a few have chronic hemolysis.
With the most prevalent G6PD variants (G6PD A- and G6PD
Mediterranean), severe hemolysis is induced by the sudden
destruction of older, more deficient erythrocytes after
exposure to drugs with a high redox potential or to fava
beans, selected infections, or metabolic abnormalities. The
likelihood of developing hemolysis and the severity of
disease are determined by the magnitude of the enzyme
deficiency, which in turn is determined by biochemical
characteristics of the G6PD variant. The World Health
Organization has classified the different G6PD variants
according to the magnitude of the enzyme deficiency and
the severity of hemolysis.17 Class I variants are character-
ized by severe enzyme deficiency (less than 10% of normal)
and are associated with chronic hemolytic anemia. Class II
variants also are associated with severe enzyme deficiency,
but are usually only intermittently associated with hemo-
lysis. Class III variants are associated with moderate
enzyme deficiency (10 to 60% of normal) with intermittent
hemolysis usually associated with infection or drugs. Class
IV variants have no enzyme deficiency or hemolysis. Class V
variants have increased enzyme activity. Classes IV and V
are of no clinical significance. The incidence of hemolysis
development in patients with G6PD deficiency after taking
aspirin is related to dosage.18 G6PD deficiency is commonly
considered a contraindication to aspirin intake. However,
a few studies12 have suggested that aspirin can be safely
administered in therapeutic doses to G6PD-deficient
patients without nonspherocytic hemolytic anemia. Anti-
platelet therapy is most commonly used to prevent
thrombotic events in adults with atherosclerotic vascular
disease, and for certain types of congenital heart disease in
children, stroke, and KD.19 Unfortunately, very few data on
the efficacy and safety of antiplatelet therapy for pediatric
patients, and even patients with G6PD, are available. No
prospective data exist to guide clinicians in choosing an
optimal regimen. Therapeutic regimens used in patients
with KD depend on the severity of CAL and include anti-
platelet therapy with aspirin, with or without dipyridamole
or clopidogrel; anticoagulant therapy with warfarin or low-
molecular-weight heparin; or a combination of anticoagu-
lant and antiplatelet therapy.8
A few articles have reported G6PD-deficient patients
with sustained KD.20 However, the question of whether
aspirin is suitable for KD patients with G6PD deficiency
remains unanswered. Because aspirin has hemolytic
potential in patients with G6PD deficiency, and because of
its controversial role in the acute phase of KD, we did not
prescribe aspirin for this patient. The fever subsided after
single high-dose IVIG treatment with a good disease
outcome (neither IVIG resistance nor CAL formation), which
may support the necessary role of high-dose aspirin in the
treatment of KD in the acute phase.Conflicts of interest
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